Institucionalizando las cuentas de salud en Brasil Una revisión de los métodos, datos y relevancia política Institucionalizando las cuentas de salud en Brasil Una revisión de los métodos, datos y relevancia política Institucionalizando las cuentas de salud en Brasil UNA REVISIÓN DE LOS MÉTODOS, DATOS Y RELEVANCIA POLÍTICA El presente trabajo se publica bajo la responsabilidad del Secretario General de la OCDE. Las opiniones expresadas y los argumentos utilizados en el mismo no reflejan necesariamente el pun ...

Aier Eye Hospital AIC 2025: Premiumisation of refractive business; aiming to improve 2025 margins 更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha abc 3 June 2025 First Read 2025 targets: Improve margins and ASPs for refractive business We invited Aier to participate in the UBS 2025 AIC. Given macro uncertainties, the company did not provide guidance for 2025, but highlighted its targets of improving margins and ASPs for refractive business. The performance of the refractive and optometry business was lackluster in April, w ...

Core Points - Equasens Group will hold its Annual Ordinary General Meeting on June 25, 2025, at 5:30 PM at its registered office in Villers-lès-Nancy [2] - The agenda and resolutions for the meeting were published in the French legal announcements on May 16, 2025 [3] - The Meeting Notice was published on June 6, 2025, detailing participation and voting procedures [4] Company Information - Equasens Group, founded over 35 years ago, is a leader in digital healthcare solutions, employing over 1,300 people across Europe [8] - The company provides specialized business applications that support healthcare professionals in various settings, including private practice and healthcare establishments [9] - Equasens Group focuses on interoperability solutions that enhance coordination among healthcare professionals, improving patient care and system efficiency [10] Meeting Logistics - The Annual General Meeting will be broadcast live online, with connection information available 48 hours prior to the meeting [7] - A replay of the meeting will also be accessible on the company's website for later viewing [7] - All relevant documents and voting forms are available on the company's website since June 4, 2025 [5]

Core Insights - Tempus AI (TEM) is on track to achieve a significant milestone in its 10th year, projecting a full-year adjusted EBITDA of $5 million, which represents an improvement of approximately $110 million over 2024 [1] - The company narrowed its adjusted EBITDA loss by $27.8 million year over year to negative $16.2 million, indicating effective cost management [1][10] Revenue and Profitability - First-quarter revenues surged by 75.4% year over year, driven by an 89% increase in Genomics, a 31% rise in Oncology testing, and a $63.5 million contribution from Hereditary testing [2] - Gross profit increased at an even higher rate of 99.8% year over year, nearly doubling the growth rate from the previous quarter, supported by gross margin expansion in Genomics and Data and services [2] Competitive Landscape - Compared to older peers like Guardant Health and Myriad Genetics, which are still facing significant annual losses, Tempus is experiencing rapid growth and margin improvements, positioning itself for a promising shift to profitability [3] - Guardant Health reported an adjusted EBITDA loss of $58.5 million for Q1 2025, while Myriad Genetics posted an adjusted EBITDA near breakeven [4][5] Stock Performance - Year to date, Tempus AI shares have increased by 71.8%, significantly outperforming the industry average growth of 22.9% [8][10] - The stock trades at a forward 12-month sales multiple of 7.36X, which is lower than its median of 28.64X but above the industry average of 6.03X [9]

Core Viewpoint - UnitedHealth Group (UNH) has experienced significant negative news, leading to a substantial decline in share price, which is now perceived as reaching value levels [1]. Group 1: Company Performance - UNH's share price has decreased significantly, reflecting a "whopping" drop since the last analysis at the end of 2024 [1]. Group 2: Analyst Perspective - The analysis suggests that the current share price of UNH presents a potential investment opportunity due to its perceived undervaluation [1].

2 June 2025 | 2:08AM PDT Americas Healthcare: MedTech & HCIT: Leaning Into Growth and Reinvestment Thesis Heading to the halfway point of 2025 and the Goldman Sachs 46th Annual Healthcare Conference, we review takeaways from YTD results, market due diligence, and management meetings that set the foundation for the balance of the year. The following summarizes key takeaways from a fundamental perspective: David Roman +1(212)357-4617 | david.roman@gs.com Goldman Sachs & Co. LLC Jamie Perse, CFA +1(212)902-819 ...

Core Points - MEDIROM Healthcare Technologies Inc. has regained compliance with Nasdaq's minimum bid price requirement as of June 4, 2025 [1][3] - The company was previously notified on February 27, 2025, that it was not in compliance, needing to maintain a minimum closing bid price of $1.00 per share for at least 10 consecutive business days [2] - The closing bid price of the company's American Depositary Shares (ADSs) was $1.00 or greater for the required period from May 20, 2025, to June 3, 2025 [3] Company Overview - MEDIROM operates over 300 wellness salons in Japan, with its leading brand being Re.Ra.Ku® [4] - The company entered the health tech business in 2015 and launched an on-demand training app called "Lav®" [4] - In 2020, MEDIROM developed a smart tracker, the "MOTHER Bracelet®," and in 2023, it launched REMONY, a remote monitoring system for corporate clients across various industries [4] - MEDIROM aims to leverage its diverse portfolio to collect and manage healthcare data, positioning itself as a leader in healthcare big data in Japan [4]

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style S ...

One of the most exciting growth stories in the market is that of Hims & Hers Health Inc. NYSE: HIMS. This company has combined the growth and efficiency aspects of the technology sector with the safety and stability of the medical sector. With this mixture in the business model, investors have the best of both worlds, allowing them to move forward with further upside potential. Hims & Hers Health Today HIMS Hims & Hers Health $53.78 -0.95 (-1.74%) $72.98 P/E Ratio 122.23 Price Target $38.00 Add to Watchlist ...

Core Insights - Waterdrop Inc. reported a net operating revenue of RMB 753.7 million and a net profit of RMB 108.2 million for Q1 2025, marking a 34.2% increase year-over-year and achieving profitability for the thirteenth consecutive quarter [1] - The company has repurchased approximately 54.2 million American Depositary Shares (ADSs) since initiating its share repurchase program in September 2021 [2] Financial Performance - Insurance-related revenue reached RMB 658.0 million, an 8.4% increase year-over-year, with operating profit from the insurance business totaling RMB 151.4 million [3] - First-year premiums (FYPs) from the insurance business amounted to RMB 2,092.4 million, reflecting a 19.3% year-over-year increase [3] Business Growth and Innovation - Waterdrop's insurance business experienced a 30.1% year-over-year increase in short-term premiums, driven by refined user acquisition strategies and product innovation, including the upgrade of the "Jiehaoyun" product to version 5.0 [4] - The introduction of the Million Medical Insurance product offers unique features such as a health declaration waiver and guaranteed renewal for five consecutive years [4] Technological Advancements - The "AI Insurance Expert - Medical Insurance" application facilitated over RMB 2 million in monthly premiums, while the "AI Service Quality Copilot" improved operational efficiency by 83% [5] - Waterdrop has partnered with four property and casualty insurers to pilot AI-driven applications in the auto insurance sector [5] Social Impact - Waterdrop Medical Crowdfunding has raised a cumulative total of RMB 68.8 billion for 3.47 million patients, with around 475 million people participating in donations [6] - The Digital Clinical Trial Solution generated revenues of approximately RMB 23.0 million, an 11.5% year-over-year increase, with 11,217 patients enrolled in clinical trial programs [7] Leadership Commentary - The CEO emphasized the solid revenue and profit growth in Q1, highlighting the role of AI in enhancing service quality and the commitment to tech-driven value creation [8]